BRPI1008356A2 - "sal de adição ácido de udenafil, respectivo método de preparação e composição farmacêutica" - Google Patents

"sal de adição ácido de udenafil, respectivo método de preparação e composição farmacêutica"

Info

Publication number
BRPI1008356A2
BRPI1008356A2 BRPI1008356-1A BRPI1008356A BRPI1008356A2 BR PI1008356 A2 BRPI1008356 A2 BR PI1008356A2 BR PI1008356 A BRPI1008356 A BR PI1008356A BR PI1008356 A2 BRPI1008356 A2 BR PI1008356A2
Authority
BR
Brazil
Prior art keywords
udenafil
preparation
pharmaceutical composition
acid addition
addition salt
Prior art date
Application number
BRPI1008356-1A
Other languages
English (en)
Inventor
Chan-Ho Lee
Chang-Yong Shin
Seul-Min Choi
Kyung-Koo Kang
Dong-Seong Kim
Byoung-Ok Ahn
Moo-Hi Yoo
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of BRPI1008356A2 publication Critical patent/BRPI1008356A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1008356-1A 2009-02-18 2010-02-17 "sal de adição ácido de udenafil, respectivo método de preparação e composição farmacêutica" BRPI1008356A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090013350A KR101071877B1 (ko) 2009-02-18 2009-02-18 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
PCT/KR2010/000976 WO2010095849A2 (en) 2009-02-18 2010-02-17 Acid addition salt of udenafil, preparation method thereof and phamaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
BRPI1008356A2 true BRPI1008356A2 (pt) 2015-08-25

Family

ID=42634317

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008356-1A BRPI1008356A2 (pt) 2009-02-18 2010-02-17 "sal de adição ácido de udenafil, respectivo método de preparação e composição farmacêutica"

Country Status (12)

Country Link
US (1) US20110306762A1 (pt)
EP (1) EP2398804A4 (pt)
JP (1) JP2012517999A (pt)
KR (1) KR101071877B1 (pt)
CN (1) CN102325774A (pt)
AU (1) AU2010216577A1 (pt)
BR (1) BRPI1008356A2 (pt)
CA (1) CA2751639A1 (pt)
MX (1) MX2011008644A (pt)
RU (1) RU2011134011A (pt)
SG (1) SG173733A1 (pt)
WO (1) WO2010095849A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220098A2 (en) * 2007-12-12 2010-08-25 Ultimorphix Technologies B.v. Solid forms of tenofovir disoproxil
TWI462739B (zh) * 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
AU2015302271B2 (en) * 2014-08-12 2019-02-28 Children’s Hospital of Philadelphia Methods of improving myocardial performance in fontan patients using udenafil compositions
EP3436455A4 (en) * 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
AU2020356193A1 (en) 2019-09-24 2022-05-19 Children's Hospital Of Philadelphia Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
KR101304343B1 (ko) * 2006-04-06 2013-09-11 한미사이언스 주식회사 Ｐｄｅ-5 억제제의 경구용 속용제형
WO2008070313A2 (en) * 2006-10-20 2008-06-12 Concert Pharmaceuticals Inc. 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
EP2106792A1 (en) * 2008-04-02 2009-10-07 Pelvipharm Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder

Also Published As

Publication number Publication date
CA2751639A1 (en) 2010-08-26
WO2010095849A2 (en) 2010-08-26
KR101071877B1 (ko) 2011-10-10
EP2398804A4 (en) 2012-08-15
US20110306762A1 (en) 2011-12-15
JP2012517999A (ja) 2012-08-09
SG173733A1 (en) 2011-09-29
MX2011008644A (es) 2011-09-27
CN102325774A (zh) 2012-01-18
RU2011134011A (ru) 2013-03-27
AU2010216577A1 (en) 2011-09-01
EP2398804A2 (en) 2011-12-28
WO2010095849A3 (en) 2010-12-09
KR20100094097A (ko) 2010-08-26

Similar Documents

Publication Publication Date Title
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
HRP20130606T1 (en) Composition having biocide activity for aqueous preparations
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
BRPI1011414A8 (pt) "método."
ZA201106299B (en) Composition comprising caftaric acid and/or derivatives thereof
BRPI0816234A2 (pt) Derivado de ácido ascórbico ou sal do mesmo, método de produção do mesmo, e cosmético
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
AP3542A (en) Anti-malarial pharmaceutical composition
BRPI1007194A2 (pt) Composição compreendendo ácido chicórico e/ou derivados do mesmo
IL235943A0 (en) Genistein salts, crystalline forms of same, compositions comprising same and uses thereof
PT2193795E (pt) Composição farmacêutica aquosa contendo latanoprost
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
EP2415869A4 (en) MODIFIED OLIGO-NUCLEIC ACID MOLECULE, PROCESS FOR PREPARATION AND USES THEREOF
IL216105A0 (en) Non-cating salt composition, preparation process and use thereof
ZA200900237B (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
PL2504331T3 (pl) Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie
PL1988090T3 (pl) Pochodne kwasu imidazolo-5-karboksylowego, sposoby przygotowania i ich zastosowanie
BRPI1011822A2 (pt) "compostos de 3-substituída-8-substituída-3h-imidazo[5,1-d][1,2,3,5-tetrazin-4-ona e sua aplicação"
IL193384A0 (en) Substituted prolinamides, their preparation and their use as pharmaceuticals
ZA201105542B (en) Cefdinir acid double salt and its preparation
IL214028A (en) A cyanopyrimidine or salt compound, a pharmaceutical preparation containing it, its use and an aqueous liquid containing the said pharmaceutical composition
IL201912A0 (en) Aqueous pharmaceutical composition
ZA201004864B (en) Amino acid derivatives used as pharmaceutical substances

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.